JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Scope & Guideline

Transforming Patient Care Through Cutting-Edge Research

Introduction

Welcome to the JOURNAL OF THROMBOSIS AND HAEMOSTASIS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of JOURNAL OF THROMBOSIS AND HAEMOSTASIS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1538-7933
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2003 to 2024
AbbreviationJ THROMB HAEMOST / J. Thromb. Haemost.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The Journal of Thrombosis and Haemostasis focuses on advancing the understanding of thrombosis and hemostasis through innovative research, clinical studies, and guidelines. It encompasses a broad spectrum of topics related to blood coagulation, bleeding disorders, and thrombotic diseases, with an emphasis on translational research that bridges the gap between laboratory science and clinical application.
  1. Thrombosis and Hemostasis Mechanisms:
    Investigates the fundamental biological processes underlying thrombosis and hemostasis, including coagulation pathways, platelet function, and the role of the endothelium.
  2. Bleeding Disorders:
    Focuses on the diagnosis, treatment, and management of inherited and acquired bleeding disorders, such as hemophilia, von Willebrand disease, and others.
  3. Anticoagulation and Thrombotic Risk Management:
    Explores the efficacy and safety of anticoagulant therapies, risk assessment strategies, and guidelines for managing patients at risk of thromboembolic events.
  4. Clinical Trials and Innovations:
    Reports on novel therapeutic approaches, including gene therapies, monoclonal antibodies, and emerging anticoagulants, aimed at improving patient outcomes.
  5. Translational Research:
    Emphasizes studies that translate laboratory findings into clinical practice, providing insights that can directly impact patient care in thrombosis and hemostasis.
  6. Guidelines and Best Practices:
    Provides updates and consensus guidelines from leading experts and committees on the management of various thrombotic and bleeding disorders.
The Journal of Thrombosis and Haemostasis has identified several emerging themes in thrombosis and hemostasis research, reflecting current trends and the evolving landscape of clinical and laboratory practices. These areas are gaining prominence due to their relevance and potential impact on patient management.
  1. Gene Therapy for Hemophilia:
    Emerging studies on gene therapy approaches for hemophilia treatment are on the rise, showcasing innovative strategies to address genetic deficiencies in coagulation factors.
  2. COVID-19 Related Thrombosis Research:
    Significant attention is being given to the thrombotic complications associated with COVID-19, including mechanisms, management, and long-term outcomes.
  3. Personalized Medicine in Thrombosis Management:
    Research focusing on individualized treatment strategies, including the use of genetic and phenotypic markers to guide anticoagulation therapy, is gaining traction.
  4. Impact of Inflammation on Coagulation:
    Studies exploring the relationship between inflammation and coagulation pathways are becoming increasingly relevant, particularly in chronic diseases and infection contexts.
  5. Advanced Imaging and Biomarker Studies:
    There is a growing interest in the use of advanced imaging techniques and biomarker identification to improve the diagnosis and management of thrombotic disorders.

Declining or Waning

While the Journal of Thrombosis and Haemostasis continues to thrive in various research areas, certain themes have shown a decline in focus over recent years. This may reflect shifts in research priorities or advancements in the field that have made some topics less prominent.
  1. Traditional Diagnostic Assays:
    There is a noticeable decrease in studies focused solely on traditional diagnostic assays for coagulation disorders, as newer, more advanced methodologies gain traction.
  2. Basic Science Without Clinical Relevance:
    Research that does not directly translate into clinical applications or patient outcomes appears to be receiving less attention, as the journal emphasizes studies with clear implications for patient care.
  3. Pharmacological Interventions with Limited Evidence:
    Topics that discuss pharmacological interventions lacking robust clinical trial data or clear efficacy are becoming less common, as the journal's readership seeks evidence-based findings.
  4. Historical Perspectives:
    Papers centered on historical analyses of thrombosis and hemostasis are decreasing, possibly as the focus shifts towards innovative and forward-looking research.

Similar Journals

Journal of Atherosclerosis and Thrombosis

Leading the charge in cardiovascular research excellence.
Publisher: JAPAN ATHEROSCLEROSIS SOCISSN: 1340-3478Frequency: 12 issues/year

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Advancing the Science of Blood Health
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Exploring the frontiers of cardiovascular medicine and innovation.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1079-5642Frequency: 12 issues/year

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Elevating discourse in cardiovascular medicine.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

Annals of Vascular Diseases

Pioneering Insights in Vascular Health
Publisher: ANNALS VASCULAR DISEASES EDITORIAL OFFICEISSN: 1881-641XFrequency: 4 issues/year

Annals of Vascular Diseases is a leading international journal dedicated to the comprehensive exploration of vascular pathology, aimed at advancing knowledge in the field through innovative research and insightful reviews. Published by the ANNALS VASCULAR DISEASES EDITORIAL OFFICE and available in both print (ISSN: 1881-641X) and electronic format (E-ISSN: 1881-6428), this journal has embraced Open Access since 2017, facilitating wider dissemination and accessibility of vital research findings. With its focus on clinical and experimental studies relating to vascular diseases, the journal serves as a crucial platform for researchers, medical professionals, and students who seek to stay at the forefront of clinical advancements. By fostering collaboration and sharing knowledge, Annals of Vascular Diseases plays a significant role in shaping the future of vascular research and treatment strategies worldwide.

AMERICAN JOURNAL OF HEMATOLOGY

Advancing Hematological Science Through Rigorous Research
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION

Advancing the Science of Blood Flow and Microcirculation
Publisher: IOS PRESSISSN: 1386-0291Frequency: 8 issues/year

Clinical Hemorheology and Microcirculation, published by IOS Press, is a distinguished journal dedicated to advancing the scientific understanding of blood flow mechanics and microcirculatory phenomena. Since its inception in 1991, the journal has been pivotal in bridging the fields of cardiology, hematology, and physiology, as evidenced by its placement in the Q3 quartile across several categories in 2023. Positioned in the vibrant academic landscape of the Netherlands, Clinical Hemorheology and Microcirculation offers valuable insights to researchers and practitioners alike, enriching their knowledge and fostering innovation in clinical practices. With an ISSN of 1386-0291 and an E-ISSN of 1875-8622, the journal serves as a vital platform for disseminating high-quality research and reviews that explore the intricate dynamics of blood viscosity and microvascular function, essential to both health and disease. As readers delve into the journal, they will access rigorous studies that not only enhance theoretical understanding but also pave the way for potential clinical applications, making it a crucial resource for those invested in the future of cardiovascular and hematological research.

Journal of Hematology

Exploring the Depths of Hematological Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

SEMINARS IN THROMBOSIS AND HEMOSTASIS

Innovating research for better patient outcomes.
Publisher: THIEME MEDICAL PUBL INCISSN: 0094-6176Frequency: 8 issues/year

SEMINARS IN THROMBOSIS AND HEMOSTASIS is a prestigious academic journal dedicated to advancing the understanding and practice of thrombosis and hemostasis, published by THIEME MEDICAL PUBL INC. With an ISSN of 0094-6176 and an E-ISSN of 1098-9064, this journal plays a critical role in disseminating groundbreaking research and reviews in the fields of cardiology and hematology. As of 2023, it holds a commendable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Hematology categories, with Scopus ranks of #55 out of 387 and #23 out of 137, respectively, positioning it within the top percentiles of these disciplines. The journal publishes articles that bring forth innovative findings and facilitate clinical applications, making it an essential resource for researchers, healthcare professionals, and students focused on improving patient care and outcomes. Since its inception in 1974, SEMINARS IN THROMBOSIS AND HEMOSTASIS continues to evolve with the changing landscape of medical research, striving to fill the gaps in knowledge and foster an informed approach to hemostatic disorders.

HAEMOPHILIA

Innovating the future of hemophilia treatment.
Publisher: WILEYISSN: 1351-8216Frequency: 6 issues/year

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.